Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | ECE1 | P42892 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1275889 | 0.85 | CYP2D6 (0.65) | CYP2D6CYP2C19MAPTEPHX1LMNA | |
| SCHEMBL17373960 | 0.80 | EGLN1 (0.48) | MAPTLMNAALDH1A1PTGS2TDP1 | |
| SCHEMBL27322897 | 0.78 | EPHX1 (0.56) | CYP2D6CYP2C19MAPTEPHX1MMP1 | |
| SCHEMBL12709660 | 0.78 | EPHX1 (0.47) | CYP2D6CYP2C19MAPTEPHX1LMNA | |
| SCHEMBL10224058 | 0.77 | EPHX1 (0.60) | CYP2D6CYP2C19MAPTEPHX1LMNA | |
| SCHEMBL965868 | 0.76 | EPHX1 (0.59) | CYP2D6CYP2C19MAPTEPHX1LMNA | |
| SCHEMBL18782866 | 0.74 | CYP2D6 (0.52) | CYP2D6CYP2C19MAPTEPHX1LMNA | |
| SCHEMBL11661134 | 0.74 | ALDH1A1 (0.50) | CYP2D6CYP2C19MAPTEPHX1LMNA | |
| SCHEMBL15148253 | 0.74 | CYP2D6 (0.52) | CYP2D6CYP2C19MAPTEPHX1LMNA | |
| SCHEMBL16801793 | 0.74 | CYP2D6 (0.52) | CYP2D6CYP2C19MAPTEPHX1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057971-B1 | 1-(BETA-D-GLUCOPYRANOSYL)-1H-INDOLE COMPOUNDS | LILLY CO ELI (US) | 2018-12-12 | — | — | EP | disclosed |
| EP-3063162-B1 | GLUCOPYRANOSYL-SUBSTITUTED INDOLE-UREA DERIVATIVES AND THEIR USE AS SGLT INHIBITORS | LILLY CO ELI (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-3063162-B1 | GLUCOPYRANOSYL-SUBSTITUTED INDOLE-UREA DERIVATIVES AND THEIR USE AS SGLT INHIBITORS | LILLY CO ELI (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-3063162-A1 | GLUCOPYRANOSYL-SUBSTITUTED INDOLE-UREA DERIVATIVES AND THEIR USE AS SGLT INHIBITORS | Eli Lilly and Company (US) | 2016-09-07 | — | — | EP | disclosed |
| EP-3057971-A1 | 1 -(BETA-D-GLUCOPYRANOSYL)-1H-INDOLE COMPOUNDS | Eli Lilly and Company (US) | 2016-08-24 | — | — | EP | disclosed |
| US-9145435-B2 | Urea compounds | ELI LILLY AND COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145437-B2 | Urea compounds | ELI LILLY AND COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145437-B2 | Urea compounds | ELI LILLY AND COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145437-B2 | Urea compounds | ELI LILLY AND COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145435-B2 | Urea compounds | ELI LILLY AND COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150126469-A1 | NOVEL UREA COMPOUNDS | LILLY CO ELI (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126469-A1 | NOVEL UREA COMPOUNDS | LILLY CO ELI (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126469-A1 | NOVEL UREA COMPOUNDS | LILLY CO ELI (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150111846-A1 | NOVEL UREA COMPOUNDS | ELI LILLY AND COMPANY | 2015-04-23 | — | — | US | disclosed |
| US-20150111846-A1 | NOVEL UREA COMPOUNDS | ELI LILLY AND COMPANY | 2015-04-23 | — | — | US | disclosed |
| US-20150111846-A1 | NOVEL UREA COMPOUNDS | ELI LILLY AND COMPANY | 2015-04-23 | — | — | US | disclosed |
| WO-2015057953-A1 | 1 -(BETA-D-GLUCOPYRANOSYL)-1H-INDOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015057953-A1 | 1 -(BETA-D-GLUCOPYRANOSYL)-1H-INDOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2015-04-23 | — | — | WO | disclosed |
| CN-103539703-A | Synthesis method of 2-(3-isobutyl ureido) acetate | WUXI APPTEC TIANJIN CO LTD | 2014-01-29 | — | — | CN | disclosed |
| CN-103539703-A | Synthesis method of 2-(3-isobutyl ureido) acetate | WUXI APPTEC TIANJIN CO LTD | 2014-01-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111846-A1 | NOVEL UREA COMPOUNDS | SLC14A1, SLC10A1, UTS2R | CYP2D6 1316/4885CYP2C19 1019/4885MAPT 768/4885 |
| US-20150126469-A1 | NOVEL UREA COMPOUNDS | SLC14A1, SLC10A1, UTS2R | CYP2D6 1316/4885CYP2C19 1019/4885MAPT 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.